drug

Risperidal Consta

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Réseau de Santé Vitalité Health Network
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
NCT03390712—Unknown
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
NCT00299702Phase 4Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Réseau de Santé Vitalité Health Network
company
trial
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
trial
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
PHASE4
trial
indication
Schizophrenia
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
Recurrence
indication